Asuragen, Inc. and Fragile X Collaborators Report Findings Using a Novel Methylation PCR Technology to Characterize the FMR1 Gene

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announces results from an evaluation of a breakthrough PCR technology that determines the methylation status of the fragile X gene. The study was published in collaboration with researchers at the University of California Davis M.I.N.D. Institute in the June issue of Genetics in Medicine, the official journal of the American College of Medical Genetics and a leading publication for innovative, clinically-directed genetics research.

Back to news